A meta-analysis of clinical benefit rates for fulvestrant 500 mg versus alternative therapies for treatment of postmenopausal, estrogen receptor-positive advanced breast cancer

被引：1
|
作者：
Robertson, J. F. R.
Zefei, J.
Di Leo, A.
Ohno, S.
Pritchard, K. I.
Ellis, M.
Bradbury, I.
Campbell, C.
机构：
[1] Univ Nottingham, Div Breast Surg, Nottingham NG7 2RD, England
[2] Chinese Peoples Liberat Army, Hosp 307, Beijing, Peoples R China
[3] Hosp Prato, Sandro Pitigliani Med Oncol Unit, Prato, Italy
[4] Canc Inst Hosp, Breast Oncol Ctr, Tokyo, Japan
[5] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[6] Univ Toronto, Toronto, ON, Canada
[7] Baylor Coll Med, Houston, TX 77030 USA
[8] Frontier Sci, Kingussie, Inverness, Scotland
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P5-14-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-14-01
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A network meta-analysis of fulvestrant 500 mg versus alternative therapies for second-line treatment of postmenopausal, estrogen receptor-positive advanced breast cancer
    Telford, C.
    Jones, N.
    Batson, S.
    CANCER RESEARCH, 2016, 76
  • [2] A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer
    Robertson, John F. R.
    Jiang, Zefei
    Di Leo, Angelo
    Ohno, Shinji
    Pritchard, Kathleen I.
    Ellis, Matthew
    Bradbury, Ian
    Campbell, Christine
    BREAST CANCER, 2019, 26 (06) : 703 - 711
  • [3] A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer
    John F. R. Robertson
    Zefei Jiang
    Angelo Di Leo
    Shinji Ohno
    Kathleen I. Pritchard
    Matthew Ellis
    Ian Bradbury
    Christine Campbell
    Breast Cancer, 2019, 26 : 703 - 711
  • [4] Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy
    Telford, Claire
    Jones, Nick
    Livings, Christopher
    Batson, Sarah
    CLINICAL BREAST CANCER, 2016, 16 (03) : 188 - 195
  • [5] Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer
    Di Leo, Angelo
    Jerusalem, Guy
    Petruzelka, Lubos
    Torres, Roberto
    Bondarenko, Igor N.
    Khasanov, Rustem
    Verhoeven, Didier
    Pedrini, Jose L.
    Smirnova, Iya
    Lichinitser, Mikhail R.
    Pendergrass, Kelly
    Garnett, Sally
    Lindemann, Justin P. O.
    Sapunar, Francisco
    Martin, Miguel
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) : 4594 - 4600
  • [6] Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China
    Zhang, Qingyuan
    Shao, Zhimin
    Shen, Kunwei
    Li, Li
    Feng, Jifeng
    Tong, Zhongsheng
    Gu, Kangsheng
    Wang, Xiaojia
    Xu, Binghe
    Sun, Guofang
    Chen, Huifang
    Rukazenkov, Yuri
    Jiang, Zefei
    ONCOTARGET, 2016, 7 (35) : 57301 - 57309
  • [7] CONFIRM: A Phase III, Randomized, Parallel-Group Trial Comparing Fulvestrant 250 mg vs Fulvestrant 500 mg in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer
    Di Leo, A.
    Jerusalem, G.
    Petruzelka, L.
    Torres, R.
    Bondarenko, I
    Khasanov, R.
    Verhoeven, D.
    Pedrini, J.
    Lichinitser, M.
    Pendergrass, K.
    Garnett, S.
    Lindemann, J. P. O.
    Sapunar, F.
    Martin, M.
    CANCER RESEARCH, 2009, 69 (24) : 491S - 491S
  • [8] Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis
    Wang, Jiayu
    Xu, Binghe
    Wang, Wenna
    Zhai, Xiaoyu
    Chen, Xuelian
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (03) : 535 - 544
  • [9] Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis
    Jiayu Wang
    Binghe Xu
    Wenna Wang
    Xiaoyu Zhai
    Xuelian Chen
    Breast Cancer Research and Treatment, 2018, 171 : 535 - 544
  • [10] Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer (vol 28, pg 4594, 2010)
    Di Leo, A.
    Jerusalem, G.
    Petruzelka, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) : 2293 - 2293
12345